<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00272480</url>
  </required_header>
  <id_info>
    <org_study_id>BRIDGE1.0</org_study_id>
    <nct_id>NCT00272480</nct_id>
  </id_info>
  <brief_title>Zidovudine Plus Lamivudine in HTLV-I-associated Myelopathy: a Randomised Trial</brief_title>
  <official_title>Zidovudine Plus Lamivudine in HTLV-I-associated Myelopathy: a Randomised Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine whether the use of two antiviral agents in combination will be better than
      placebo in the treatment of an inflammatory sidease of the spinal cord caused by HTLV-I
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomised, double-blind, placebo-controlled two centre study of zidvoudine plus lamivudine
      in HAM/TSP 24 patients randomised 1:1 2-4 week lead-in 6 months randomised phase followed by
      6 months open-label therapy with active drug Primary endpoint: clinical Secondary endpoints:
      virological and immunological
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 8, 1999</start_date>
  <completion_date type="Actual">July 30, 2002</completion_date>
  <primary_completion_date type="Actual">July 30, 2002</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Timed walk</measure>
    <time_frame>6 months</time_frame>
    <description>Time taken to walk 13m</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Osame's Motor Disability Score</measure>
    <time_frame>6 months</time_frame>
    <description>0 - 4 (Unaided walk), 5 - 8 (Needs aid to walk), 9 - 13 (Unable to walk)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain score</measure>
    <time_frame>6 months</time_frame>
    <description>11 point Visual Analogue Scale 0 = no pain, 10 = worse pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary frequency</measure>
    <time_frame>6 months</time_frame>
    <description>Number of times passing urine during the daytime</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HTLV-1 proviral load</measure>
    <time_frame>6 months</time_frame>
    <description>The number of copies of HTLV DNA in 100 peripheral blood mononuclear cells</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CD25%</measure>
    <time_frame>6 months</time_frame>
    <description>Expression of CD25 on T-cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HLA-DR%</measure>
    <time_frame>6 months</time_frame>
    <description>Expression of HLA-DR on T-cells</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>HTLV-I-associated Myelopathy</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo in HAM/TSP 24</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zidvoudine plus lamivudine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Zidvoudine plus lamivudine in HAM/TSP 24</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine/lamivudine</intervention_name>
    <arm_group_label>Zidvoudine plus lamivudine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HTLV-I-associated myelopathy

        Exclusion Criteria:

          -  prior exposure to zidovudine or lamivudine on disease modifying therapy

          -  under age 16
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Graham P Taylor, FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Imperial College</name>
      <address>
        <city>London</city>
        <zip>W2 1PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Taylor GP et al The Bridge Study - A double-blind, placebo controlled trial of zidovudine plus lamivudine for the treatment of patients with HTLV-I-associated myelopathy AIDS Research and Human Retroviruses 2003;19 (suppl 1) #O23</citation>
  </reference>
  <results_reference>
    <citation>Taylor GP, Goon P, Furukawa Y, Green H, Barfield A, Mosley A, Nose H, Babiker A, Rudge P, Usuku K, Osame M, Bangham CR, Weber JN. Zidovudine plus lamivudine in Human T-Lymphotropic Virus type-I-associated myelopathy: a randomised trial. Retrovirology. 2006 Sep 19;3:63.</citation>
    <PMID>16984654</PMID>
  </results_reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>January 4, 2006</study_first_submitted>
  <study_first_submitted_qc>January 4, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2006</study_first_posted>
  <last_update_submitted>July 17, 2019</last_update_submitted>
  <last_update_submitted_qc>July 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HAM/TSP</keyword>
  <keyword>HTLV-I-associated myelopathy</keyword>
  <keyword>zidovudine</keyword>
  <keyword>lamivudine</keyword>
  <keyword>antiretroviral therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paraparesis, Tropical Spastic</mesh_term>
    <mesh_term>Spinal Cord Diseases</mesh_term>
    <mesh_term>Bone Marrow Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

